Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does FOSAPREPITANT Cause Malignant neoplasm progression? 5 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with FOSAPREPITANT. This represents 1.0% of all adverse event reports for FOSAPREPITANT.

5
Reports of Malignant neoplasm progression with FOSAPREPITANT
1.0%
of all FOSAPREPITANT reports
4
Deaths
5
Hospitalizations

How Dangerous Is Malignant neoplasm progression From FOSAPREPITANT?

Of the 5 reports, 4 (80.0%) resulted in death, 5 (100.0%) required hospitalization, and 3 (60.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for FOSAPREPITANT. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does FOSAPREPITANT Cause?

Dyspnoea (195) Infusion related reaction (167) Hypersensitivity (157) Duodenal ulcer perforation (155) Confusional state (149) Glossodynia (149) Folliculitis (146) Arthralgia (144) Blister (144) Discomfort (144)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which FOSAPREPITANT Alternatives Have Lower Malignant neoplasm progression Risk?

FOSAPREPITANT vs FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT vs FOSCARBIDOPA\FOSLEVODOPA FOSAPREPITANT vs FOSCARNET FOSAPREPITANT vs FOSFOMYCIN FOSAPREPITANT vs FOSFOMYCIN TROMETHAMINE

Related Pages

FOSAPREPITANT Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression FOSAPREPITANT Demographics